Dana Narvaez, Oncologist at Alexander Fleming Institute, Global Oncology Subcommittee (Community of Practice – Health Policy) at American Society of Clinical Oncology, shared a post on LinkedIn:
“Science and Access: A Global Oncology Perspective
I’m pleased to share our recently published editorial on the MECCA trial strategy, where we discuss a low-cost, oral, and well-tolerated treatment option for patients with HR+/HER2– metastatic breast cancer. The combination of metronomic capecitabine + aromatase inhibitors may not replace targeted therapies, but it can expand options where access is limited.
Grateful to my amazing mentor Stephanie Graff and to Gerneiva Parkinson for being part of this collaborative effort.”
Title: Metronomic capecitabine plus aromatase inhibitor as initial therapy in HR-positive HER2-negative metastatic breast cancer: a low-cost and easily implementable option
Authors: Dana Narvaez, Gerneiva Parkinson, Stephanie Graff
Read the Full Article.
More posts featuring Dana Narvaez.